Xin-Xin Shao, Cong Chen, Jie Liu, Qing-Jun Li, Shan He, Xiang-Hua Qi, Xian-Jun Fu, Zhen-Guo Wang
{"title":"Lysionotin 的生物学评估:一种用于抗胶质瘤的新型 5-脂氧合酶抑制剂。","authors":"Xin-Xin Shao, Cong Chen, Jie Liu, Qing-Jun Li, Shan He, Xiang-Hua Qi, Xian-Jun Fu, Zhen-Guo Wang","doi":"10.1007/s11655-024-3763-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the potential mechanism of lysionotin in treating glioma.</p><p><strong>Methods: </strong>First, target prediction based on Bernoulli Naïve Bayes profiling and pathway enrichment was used to predict the biological activity of lysionotin. The binding between 5-lipoxygenase (5-LO) and lysionotin was detected by surface plasmon resonance (SPR) and molecular docking, and the inhibitory effects of lysionotin on 5-LO and proliferation of glioma were determined using enzyme inhibition assay in vitro and cell viability analysis, respectively. Furthermore, the pharmaceutical effect of lysionotin was explored by cell survival rate analysis and liquid chromatography with tandem mass spectrometry (LC-MS/MS). The protein expression, intracellular calcium ion concentration and cytoskeleton detection were revealed by Western blot, flow cytometry and fluorescence labeling, respectively.</p><p><strong>Results: </strong>Target prediction and pathway enrichment revealed that lysionotin inhibited 5-LO, a key enzyme involved in the arachidonic acid metabolism pathway, to inhibit the proliferation of glioma. Molecular docking results demonstrated that 5-LO can be binding to lysionotin through hydrogen bonds, forming bonds with His600, Gln557, Asn554, and His372. SPR analysis further confirmed the interaction between 5-LO and lysionotin. Furthermore, enzyme inhibition assay in vitro and cell survival rate analysis revealed that 50% inhibition concentration of lysionotin and the median effective concentration of lysionotin were 90 and 16.58 µmol/L, respectively, and the results of LC-MS/MS showed that lysionotin inhibited the production of 5S-hydroperoxy-eicosatetraenoic acid (P<0.05), and moreover, the LC-MS/MS results indicated that lysionotin can enter glioma cells well (P<0.01) and inhibit their proliferation. Western blot analysis demonstrated that lysionotin can inhibit the expression of 5-LO (P<0.05) and downstream leukotriene B4 receptor (P<0.01). In addition, the results showed that lysionotin affected intracellular calcium ion concentration by inhibiting 5-LO to affect the cytoskeleton, as determined by flow cytometry and fluorescence labeling.</p><p><strong>Conclusion: </strong>Lysionotin binds to 5-LO could suppress glioma by inhibiting arachiodonic acid metabolism pathway.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"826-834"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biological Evaluation of Lysionotin: a Novel Inhibitor of 5-Lipoxygenase for Anti-glioma.\",\"authors\":\"Xin-Xin Shao, Cong Chen, Jie Liu, Qing-Jun Li, Shan He, Xiang-Hua Qi, Xian-Jun Fu, Zhen-Guo Wang\",\"doi\":\"10.1007/s11655-024-3763-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To explore the potential mechanism of lysionotin in treating glioma.</p><p><strong>Methods: </strong>First, target prediction based on Bernoulli Naïve Bayes profiling and pathway enrichment was used to predict the biological activity of lysionotin. The binding between 5-lipoxygenase (5-LO) and lysionotin was detected by surface plasmon resonance (SPR) and molecular docking, and the inhibitory effects of lysionotin on 5-LO and proliferation of glioma were determined using enzyme inhibition assay in vitro and cell viability analysis, respectively. Furthermore, the pharmaceutical effect of lysionotin was explored by cell survival rate analysis and liquid chromatography with tandem mass spectrometry (LC-MS/MS). The protein expression, intracellular calcium ion concentration and cytoskeleton detection were revealed by Western blot, flow cytometry and fluorescence labeling, respectively.</p><p><strong>Results: </strong>Target prediction and pathway enrichment revealed that lysionotin inhibited 5-LO, a key enzyme involved in the arachidonic acid metabolism pathway, to inhibit the proliferation of glioma. Molecular docking results demonstrated that 5-LO can be binding to lysionotin through hydrogen bonds, forming bonds with His600, Gln557, Asn554, and His372. SPR analysis further confirmed the interaction between 5-LO and lysionotin. Furthermore, enzyme inhibition assay in vitro and cell survival rate analysis revealed that 50% inhibition concentration of lysionotin and the median effective concentration of lysionotin were 90 and 16.58 µmol/L, respectively, and the results of LC-MS/MS showed that lysionotin inhibited the production of 5S-hydroperoxy-eicosatetraenoic acid (P<0.05), and moreover, the LC-MS/MS results indicated that lysionotin can enter glioma cells well (P<0.01) and inhibit their proliferation. Western blot analysis demonstrated that lysionotin can inhibit the expression of 5-LO (P<0.05) and downstream leukotriene B4 receptor (P<0.01). In addition, the results showed that lysionotin affected intracellular calcium ion concentration by inhibiting 5-LO to affect the cytoskeleton, as determined by flow cytometry and fluorescence labeling.</p><p><strong>Conclusion: </strong>Lysionotin binds to 5-LO could suppress glioma by inhibiting arachiodonic acid metabolism pathway.</p>\",\"PeriodicalId\":10005,\"journal\":{\"name\":\"Chinese Journal of Integrative Medicine\",\"volume\":\" \",\"pages\":\"826-834\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Integrative Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11655-024-3763-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11655-024-3763-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨来索诺汀治疗胶质瘤的潜在机制:探索来索诺汀治疗胶质瘤的潜在机制:首先,基于伯努利奈维贝叶斯图谱和通路富集的靶点预测被用来预测来苏诺丁的生物活性。通过表面等离子体共振(SPR)和分子对接检测了5-脂氧合酶(5-LO)与来苏诺丁的结合,并利用体外酶抑制实验和细胞活力分析分别测定了来苏诺丁对5-LO和胶质瘤增殖的抑制作用。此外,还通过细胞存活率分析和液相色谱-串联质谱法(LC-MS/MS)探讨了来索诺丁的药理作用。蛋白质表达、细胞内钙离子浓度和细胞骨架的检测分别通过 Western 印迹、流式细胞仪和荧光标记法进行:结果:通过靶点预测和通路富集发现,来索诺汀可抑制参与花生四烯酸代谢通路的关键酶5-LO,从而抑制胶质瘤的增殖。分子对接结果表明,5-LO可通过氢键与来苏诺丁结合,与His600、Gln557、Asn554和His372形成键合。SPR 分析进一步证实了 5-LO 与赖氨酰烟酸之间的相互作用。此外,体外酶抑制实验和细胞存活率分析表明,来苏诺丁的50%抑制浓度和中位有效浓度分别为90 µmol/L和16.58 µmol/L,LC-MS/MS结果表明,来苏诺丁抑制了5S-氢过氧化二十碳四烯酸(PC)的产生:来索诺汀能与5-LO结合,通过抑制花生四烯酸代谢途径抑制胶质瘤。
Biological Evaluation of Lysionotin: a Novel Inhibitor of 5-Lipoxygenase for Anti-glioma.
Objective: To explore the potential mechanism of lysionotin in treating glioma.
Methods: First, target prediction based on Bernoulli Naïve Bayes profiling and pathway enrichment was used to predict the biological activity of lysionotin. The binding between 5-lipoxygenase (5-LO) and lysionotin was detected by surface plasmon resonance (SPR) and molecular docking, and the inhibitory effects of lysionotin on 5-LO and proliferation of glioma were determined using enzyme inhibition assay in vitro and cell viability analysis, respectively. Furthermore, the pharmaceutical effect of lysionotin was explored by cell survival rate analysis and liquid chromatography with tandem mass spectrometry (LC-MS/MS). The protein expression, intracellular calcium ion concentration and cytoskeleton detection were revealed by Western blot, flow cytometry and fluorescence labeling, respectively.
Results: Target prediction and pathway enrichment revealed that lysionotin inhibited 5-LO, a key enzyme involved in the arachidonic acid metabolism pathway, to inhibit the proliferation of glioma. Molecular docking results demonstrated that 5-LO can be binding to lysionotin through hydrogen bonds, forming bonds with His600, Gln557, Asn554, and His372. SPR analysis further confirmed the interaction between 5-LO and lysionotin. Furthermore, enzyme inhibition assay in vitro and cell survival rate analysis revealed that 50% inhibition concentration of lysionotin and the median effective concentration of lysionotin were 90 and 16.58 µmol/L, respectively, and the results of LC-MS/MS showed that lysionotin inhibited the production of 5S-hydroperoxy-eicosatetraenoic acid (P<0.05), and moreover, the LC-MS/MS results indicated that lysionotin can enter glioma cells well (P<0.01) and inhibit their proliferation. Western blot analysis demonstrated that lysionotin can inhibit the expression of 5-LO (P<0.05) and downstream leukotriene B4 receptor (P<0.01). In addition, the results showed that lysionotin affected intracellular calcium ion concentration by inhibiting 5-LO to affect the cytoskeleton, as determined by flow cytometry and fluorescence labeling.
Conclusion: Lysionotin binds to 5-LO could suppress glioma by inhibiting arachiodonic acid metabolism pathway.
期刊介绍:
Chinese Journal of Integrative Medicine seeks to promote international communication and exchange on integrative medicine as well as complementary and alternative medicine (CAM) and provide a rapid forum for the dissemination of scientific articles focusing on the latest developments and trends as well as experiences and achievements on integrative medicine or CAM in clinical practice, scientific research, education and healthcare.